Skip to content

Examining the pharmacokinetic and pharmacodynamic profile of biperiden

Examining the pharmacokinetic and pharmacodynamic profile of biperiden

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON24672
Enrollment
27
Registered
2017-02-09
Start date
2017-03-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

geheugen/ memory

Interventions

Subjects will participate in 3 treatment conditions: i.e. placebo, biperiden 2 mg and 4 mg. All medications will be administered orally. Order of treatments will be balanced over three test sessions,

Sponsors

Maastricht University
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements. • The participant has a body mass index of 18.5-30 kg/m2, inclusive, at medical screening. • The participant is aged 18 to 35 years, inclusive, at the time of informed consent. • The volunteer is healthy, i.e. absence of all exclusion criteria and had normal or corrected to normal static binocular acuity with or without correction. • The participant signs and dates a written informed consent form before the start of the experiments.

Exclusion criteria

Exclusion criteria: • The subject has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality which may impact the ability of the subject to participate or potentially confound the study results. • The volunteer has uncontrolled existing major psychiatric symptoms. • The participant has known hypersensitivity to any component of the formulation or biperiden or related compounds. • The subject has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the first visit or is unwilling to agree to abstain from alcohol from 24 hours prior to each test day and/or drugs throughout the study. • The participant has any sensory or motor deficits which could reasonably be expected to affect test performance. • Other exclusion criteria are smoking, excessive drinking (>20 glasses of alcohol containing beverages a week), pregnancy or lactation, use of medication other than oral contraceptives.

Design outcomes

Primary

MeasureTime frame
The main endpoints for the cognitive tasks are the behavioral score on the immediate and delayed recall of the VLT. This includes the number of words recalled immediately and after a 20 minute delay.

Secondary

MeasureTime frame
Secondary, to establish the pharmacokinetic and pharmacodynamics profile of biperiden the primary endpoints will be the blood serum values and physiological measures (body temperature, blood pressure, heart rate and pupil size). Furthermore the behavioral outcomes of the n-back and simple and choice reaction tasks will be used for analysis, as well as the scores on the B&L and complaints questionnaire. Next to this, the event-related potentials during the behavioural tasks will be analysed. Another important measure is the brain response to the novelty oddball task, which will give an indication of the role of acetylcholine in novelty processing.

Contacts

Public ContactLaura Borghans

Faculty of Psychology Dept. of Neuropsychology and Psychopharmacology

lgjm.borghans@maastrichtuniversity.nl0031-(0)43-3881530

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)